Victory Capital Management
KLDO

Victory Capital Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Victory Capital Management’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-75,075
Closed -$558K – 2591
2020
Q2 		$558K Sell
75,075
-175,297
-70% -$1.18M ﹤0.01% 1955
2020
Q1 		$1.54M Buy
250,372
+120,888
+93% +$789K ﹤0.01% 1699
2019
Q4 		$650K Sell
129,484
-4,550
-3% -$28.9K ﹤0.01% 1895
2019
Q3 		$1.01M Buy
134,034
+43,394
+48% +$377K ﹤0.01% 1698
2019
Q2 		$1.05M Sell
90,640
-5,200
-5% -$75.7K ﹤0.01% 1294
2019
Q1 		$1.39M Buy
+95,840
New +$1.32M ﹤0.01% 1175

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Victory Capital Management's KLDO Position: Q3 2020 in Review

Victory Capital Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q3 2020, closing a stake of 75,075 shares — an estimated $558K sold.

Victory Capital Management first reported a position in KLDO in Q1 2019 and held it in 6 quarters. The position peaked at $1.54M in Q1 2020. 56 funds tracked by Wall St. Rank hold KLDO as of Q3 2020.

  • Victory Capital Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Victory Capital Management sold 75,075 Kaleido Biosciences, Inc. Common Stock shares in Q3 2020, an estimated $558K.
  • Victory Capital Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 6 quarters.
  • Victory Capital Management's Kaleido Biosciences, Inc. Common Stock position peaked at $1.54M in Q1 2020.
  • 56 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q3 2020.

Based on Victory Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.